Selected research
Industry Research
Cell and Gene Therapy (CGT) Logistic Industry Research Report 2026
Market perspective
The global Cell and Gene Therapy (CGT) Logistic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cell and Gene Therapy (CGT) Logistic market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cell and Gene Therapy (CGT) Logistic market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cell and Gene Therapy (CGT) Logistic market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cell and Gene Therapy (CGT) Logistic include Cencora, Inc（World Courier）, QuickStat, Associated Couriers, LLC, Central Pharma, POLAR EXPRES, Biocair, time:matters, Mercury Business Services and Cardinal Health, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cell and Gene Therapy (CGT) Logistic market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cell and Gene Therapy (CGT) Logistic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cell and Gene Therapy (CGT) Logistic Market by Company
Cencora, Inc（World Courier）
QuickStat
Associated Couriers, LLC
Central Pharma
POLAR EXPRES
Biocair
time:matters
Mercury Business Services
Cardinal Health
CRYOPDP
Cryoport
NMDP BioTherapies
McKesson
Excel Courier
Almac
BEAM Logistics
Cell and Gene Therapy (CGT) Logistic Segment by Type
National Transportation
International Transportation
Cell and Gene Therapy (CGT) Logistic Segment by Application
Biotech and Pharmaceutical Companies
Hospitals
Research Organizations
Other
Cell and Gene Therapy (CGT) Logistic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy (CGT) Logistic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy (CGT) Logistic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy (CGT) Logistic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cell and Gene Therapy (CGT) Logistic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- National Transportation
- International Transportation
Applications
- Biotech and Pharmaceutical Companies
- Hospitals
- Research Organizations
- Other
Companies covered
- Cencora, Inc（World Courier）
- QuickStat
- Associated Couriers, LLC
- Central Pharma
- POLAR EXPRES
- Biocair
- time:matters
- Mercury Business Services
- Cardinal Health
- CRYOPDP
- Cryoport
- NMDP BioTherapies
- McKesson
- Excel Courier
- Almac
- BEAM Logistics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cell and Gene Therapy (CGT) Logistic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 National Transportation
- 2.2.3 International Transportation
- 2.3 Cell and Gene Therapy (CGT) Logistic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biotech and Pharmaceutical Companies
- 2.3.3 Hospitals
- 2.3.4 Research Organizations
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Cell and Gene Therapy (CGT) Logistic Breakdown Data by Type
- 3.1 Global Cell and Gene Therapy (CGT) Logistic Historic Market Size by Type (2021-2026)
- 3.2 Global Cell and Gene Therapy (CGT) Logistic Forecasted Market Size by Type (2027-2032)
4 Cell and Gene Therapy (CGT) Logistic Breakdown Data by Application
- 4.1 Global Cell and Gene Therapy (CGT) Logistic Historic Market Size by Application (2021-2026)
- 4.2 Global Cell and Gene Therapy (CGT) Logistic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cell and Gene Therapy (CGT) Logistic Market Perspective (2021-2032)
- 5.2 Global Cell and Gene Therapy (CGT) Logistic Growth Trends by Region
- 5.2.1 Global Cell and Gene Therapy (CGT) Logistic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cell and Gene Therapy (CGT) Logistic Historic Market Size by Region (2021-2026)
- 5.2.3 Cell and Gene Therapy (CGT) Logistic Forecasted Market Size by Region (2027-2032)
- 5.3 Cell and Gene Therapy (CGT) Logistic Market Dynamics
- 5.3.1 Cell and Gene Therapy (CGT) Logistic Industry Trends
- 5.3.2 Cell and Gene Therapy (CGT) Logistic Market Drivers
- 5.3.3 Cell and Gene Therapy (CGT) Logistic Market Challenges
- 5.3.4 Cell and Gene Therapy (CGT) Logistic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cell and Gene Therapy (CGT) Logistic Players by Revenue
- 6.1.1 Global Top Cell and Gene Therapy (CGT) Logistic Players by Revenue (2021-2026)
- 6.1.2 Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Players (2021-2026)
- 6.2 Global Cell and Gene Therapy (CGT) Logistic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cell and Gene Therapy (CGT) Logistic Head Office and Area Served
- 6.4 Global Cell and Gene Therapy (CGT) Logistic Players, Product Type & Application
- 6.5 Global Cell and Gene Therapy (CGT) Logistic Manufacturers Established Date
- 6.6 Global Cell and Gene Therapy (CGT) Logistic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032)
- 7.2 North America Cell and Gene Therapy (CGT) Logistic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cell and Gene Therapy (CGT) Logistic Market Size by Country (2021-2026)
- 7.4 North America Cell and Gene Therapy (CGT) Logistic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032)
- 8.2 Europe Cell and Gene Therapy (CGT) Logistic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cell and Gene Therapy (CGT) Logistic Market Size by Country (2021-2026)
- 8.4 Europe Cell and Gene Therapy (CGT) Logistic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032)
- 9.2 Asia-Pacific Cell and Gene Therapy (CGT) Logistic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cell and Gene Therapy (CGT) Logistic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cell and Gene Therapy (CGT) Logistic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032)
- 10.2 South America Cell and Gene Therapy (CGT) Logistic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cell and Gene Therapy (CGT) Logistic Market Size by Country (2021-2026)
- 10.4 South America Cell and Gene Therapy (CGT) Logistic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032)
- 11.2 Middle East & Africa Cell and Gene Therapy (CGT) Logistic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cell and Gene Therapy (CGT) Logistic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cell and Gene Therapy (CGT) Logistic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cencora, Inc（World Courier）
- 12.1.1 Cencora, Inc（World Courier） Company Information
- 12.1.2 Cencora, Inc（World Courier） Business Overview
- 12.1.3 Cencora, Inc（World Courier） Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.1.4 Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.1.5 Cencora, Inc（World Courier） Recent Developments
- 12.2 QuickStat
- 12.2.1 QuickStat Company Information
- 12.2.2 QuickStat Business Overview
- 12.2.3 QuickStat Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.2.4 QuickStat Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.2.5 QuickStat Recent Developments
- 12.3 Associated Couriers, LLC
- 12.3.1 Associated Couriers, LLC Company Information
- 12.3.2 Associated Couriers, LLC Business Overview
- 12.3.3 Associated Couriers, LLC Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.3.4 Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.3.5 Associated Couriers, LLC Recent Developments
- 12.4 Central Pharma
- 12.4.1 Central Pharma Company Information
- 12.4.2 Central Pharma Business Overview
- 12.4.3 Central Pharma Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.4.4 Central Pharma Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.4.5 Central Pharma Recent Developments
- 12.5 POLAR EXPRES
- 12.5.1 POLAR EXPRES Company Information
- 12.5.2 POLAR EXPRES Business Overview
- 12.5.3 POLAR EXPRES Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.5.4 POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.5.5 POLAR EXPRES Recent Developments
- 12.6 Biocair
- 12.6.1 Biocair Company Information
- 12.6.2 Biocair Business Overview
- 12.6.3 Biocair Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.6.4 Biocair Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.6.5 Biocair Recent Developments
- 12.7 time:matters
- 12.7.1 time:matters Company Information
- 12.7.2 time:matters Business Overview
- 12.7.3 time:matters Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.7.4 time:matters Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.7.5 time:matters Recent Developments
- 12.8 Mercury Business Services
- 12.8.1 Mercury Business Services Company Information
- 12.8.2 Mercury Business Services Business Overview
- 12.8.3 Mercury Business Services Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.8.4 Mercury Business Services Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.8.5 Mercury Business Services Recent Developments
- 12.9 Cardinal Health
- 12.9.1 Cardinal Health Company Information
- 12.9.2 Cardinal Health Business Overview
- 12.9.3 Cardinal Health Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.9.4 Cardinal Health Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.9.5 Cardinal Health Recent Developments
- 12.10 CRYOPDP
- 12.10.1 CRYOPDP Company Information
- 12.10.2 CRYOPDP Business Overview
- 12.10.3 CRYOPDP Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.10.4 CRYOPDP Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.10.5 CRYOPDP Recent Developments
- 12.11 Cryoport
- 12.11.1 Cryoport Company Information
- 12.11.2 Cryoport Business Overview
- 12.11.3 Cryoport Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.11.4 Cryoport Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.11.5 Cryoport Recent Developments
- 12.12 NMDP BioTherapies
- 12.12.1 NMDP BioTherapies Company Information
- 12.12.2 NMDP BioTherapies Business Overview
- 12.12.3 NMDP BioTherapies Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.12.4 NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.12.5 NMDP BioTherapies Recent Developments
- 12.13 McKesson
- 12.13.1 McKesson Company Information
- 12.13.2 McKesson Business Overview
- 12.13.3 McKesson Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.13.4 McKesson Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.13.5 McKesson Recent Developments
- 12.14 Excel Courier
- 12.14.1 Excel Courier Company Information
- 12.14.2 Excel Courier Business Overview
- 12.14.3 Excel Courier Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.14.4 Excel Courier Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.14.5 Excel Courier Recent Developments
- 12.15 Almac
- 12.15.1 Almac Company Information
- 12.15.2 Almac Business Overview
- 12.15.3 Almac Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.15.4 Almac Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.15.5 Almac Recent Developments
- 12.16 BEAM Logistics
- 12.16.1 BEAM Logistics Company Information
- 12.16.2 BEAM Logistics Business Overview
- 12.16.3 BEAM Logistics Revenue in Cell and Gene Therapy (CGT) Logistic Business (2021-2026)
- 12.16.4 BEAM Logistics Cell and Gene Therapy (CGT) Logistic Product Portfolio
- 12.16.5 BEAM Logistics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst